$6.41
1.23% today
Nasdaq, Apr 03, 06:48 pm CET
ISIN
US91678A1079
Symbol
UPB
Sector
Industry

Upstream Bio Stock price

$6.49
-0.97 13.00% 1M
-10.51 61.82% 6M
-9.95 60.52% YTD
-10.51 61.82% 1Y
-10.51 61.82% 3Y
-10.51 61.82% 5Y
-10.51 61.82% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.21 3.13%
ISIN
US91678A1079
Symbol
UPB
Sector
Industry

Key metrics

Market capitalization $348.13m
Enterprise Value $-120.49m
P/B ratio (TTM) P/B ratio 0.74
Cash position $470.45m
P/E forward negative
P/S forward 231.82
EV/Sales forward negative

Is Upstream Bio a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Upstream Bio Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Upstream Bio forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Upstream Bio forecast:

Buy
100%

Financial data from Upstream Bio

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.61 0.61
-
100%
- Direct Costs 0.05 0.05
-
8%
0.56 0.56
-
92%
- Selling and Administrative Expenses 5.06 5.06
-
830%
- Research and Development Expense 22 22
-
3,569%
-26 -26
-
-4,307%
- Depreciation and Amortization 0.05 0.05
-
8%
EBIT (Operating Income) EBIT -26 -26
-
-4,315%
Net Profit -21 -21
-
-3,482%

In millions USD.

Don't miss a Thing! We will send you all news about Upstream Bio directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Upstream Bio Stock News

Neutral
GlobeNewsWire
22 days ago
– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 –
Neutral
GlobeNewsWire
about one month ago
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Upstream Bio's CEO, will present at the following upcoming March investor conferences: TD Cowen 45th Annual Health Care Conference, Boston MA ...
Neutral
Seeking Alpha
4 months ago
Upstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug. Release of results from the phase 2 study, using verekitug for the treatment of patients with Chronic Rhinosinusitis with Nasal Polyps, expected to be released in the 2nd half of 2025. The global Chron...
More Upstream Bio News

Company Profile

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Head office United States
CEO E. Sutherland
Employees 52
Website www.upstreambio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today